1. Home
  2. TRMK vs IBRX Comparison

TRMK vs IBRX Comparison

Compare TRMK & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trustmark Corporation

TRMK

Trustmark Corporation

HOLD

Current Price

$40.25

Market Cap

2.3B

Sector

Finance

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$2.14

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRMK
IBRX
Founded
1889
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
TRMK
IBRX
Price
$40.25
$2.14
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$42.67
$9.71
AVG Volume (30 Days)
304.9K
13.4M
Earning Date
01-27-2026
11-04-2025
Dividend Yield
2.40%
N/A
EPS Growth
10.82
N/A
EPS
3.66
N/A
Revenue
$773,338,000.00
$82,555,000.00
Revenue This Year
$58.33
$667.18
Revenue Next Year
$4.57
$93.03
P/E Ratio
$10.95
N/A
Revenue Growth
55.58
1025.95
52 Week Low
$29.77
$1.83
52 Week High
$41.43
$4.27

Technical Indicators

Market Signals
Indicator
TRMK
IBRX
Relative Strength Index (RSI) 55.61 50.31
Support Level $38.47 $1.95
Resistance Level $40.56 $2.29
Average True Range (ATR) 0.70 0.10
MACD -0.13 -0.00
Stochastic Oscillator 60.21 57.47

Price Performance

Historical Comparison
TRMK
IBRX

About TRMK Trustmark Corporation

Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: